Literature DB >> 8491317

Parathyroid hormone related protein in breast cancers of widely varying prognosis.

M W Kissin1, M A Henderson, J A Danks, J A Hayman, R C Bennett, T J Martin.   

Abstract

Parathyroid hormone related protein (PTHrP) is a novel calcium regulating hormone that may have a significant role in the pathophysiology of breast cancer. We have previously demonstrated a relationship between immunohistochemically detectable PTHrP in primary breast tumours and the subsequent development of bone metastases and hypercalcaemia. The aim of this study was to compare the PTHrP status in the primary tumours from three groups of patients with widely varying prognosis. (1) The favourable outcome group; all patients had a favourable prognosis and minimum 3 years disease free follow up (n = 30). (2) The unfavourable outcome group; all patients presented with localized breast cancer but developed distant disease within 3 years (n = 26). (3) The unfavourable presentation group; all had distant disease at first presentation (n = 26). No differences in PTHrP status of the primary tumour amongst the three patient groups were found (66%, 65% and 61% positive respectively). The development of bone with liver metastases and hypercalcaemia was associated with increased positive PTHrP status of the primary tumor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8491317

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  8 in total

1.  PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target.

Authors:  Jiarong Li; Andrew C Karaplis; Dao C Huang; Peter M Siegel; Anne Camirand; Xian Fang Yang; William J Muller; Richard Kremer
Journal:  J Clin Invest       Date:  2011-11-07       Impact factor: 14.808

2.  TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases.

Authors:  Jeroen T Buijs; Keith R Stayrook; Theresa A Guise
Journal:  Cancer Microenviron       Date:  2011-07-12

Review 3.  Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine.

Authors:  Laurie K McCauley; T John Martin
Journal:  J Bone Miner Res       Date:  2012-05-01       Impact factor: 6.741

4.  Prognostic value of immunocytochemical determination of parathyroid hormone-related peptide expression in cells of mammary ductal carcinoma. Analysis of 7 years of the disease course.

Authors:  Paweł Surowiak; Piotr Dziegiel; Rafał Matkowski; Mirosław Sopel; Andrzej Wojnar; Jan Kornafel; Maciej Zabel
Journal:  Virchows Arch       Date:  2003-01-25       Impact factor: 4.064

5.  PTHrP attenuates osteoblast cell death and apoptosis induced by a novel class of anti-cancer agents.

Authors:  Sahiti Chukkapalli; Edi Levi; Arun K Rishi; Nabanita S Datta
Journal:  Endocrine       Date:  2015-08-11       Impact factor: 3.633

6.  Enhancement of taxol, doxorubicin and zoledronate anti-proliferation action on triple-negative breast cancer cells by a PTHrP blocking monoclonal antibody.

Authors:  Anne Camirand; Ibtihal Fadhil; Aimée-Lee Luco; Benoît Ochietti; Richard B Kremer
Journal:  Am J Cancer Res       Date:  2013-11-01       Impact factor: 6.166

7.  Molecular characterization of lung dysplasia induced by c-Raf-1.

Authors:  Astrid Rohrbeck; Volker Steffen Müller; Jürgen Borlak
Journal:  PLoS One       Date:  2009-05-20       Impact factor: 3.240

8.  Co-expression of parathyroid hormone related protein and TGF-beta in breast cancer predicts poor survival outcome.

Authors:  Cheng Xu; Zhengyuan Wang; Rongrong Cui; Hongyu He; Xiaoyan Lin; Yuan Sheng; Hongwei Zhang
Journal:  BMC Cancer       Date:  2015-11-23       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.